Long-term renal outcome in patients with malignant hypertension: A retrospective cohort study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Amraoui, Fouad ^a   Bos, Sarah ^a   Vogt, Liffert ^a   Van Den Born, Bert Jan ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Chronic kidney disease; End stage renal disease; Malignant hypertension; Mortality; Renal outcome

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; MORTALITY; NETHERLANDS; OUTCOME ASSESSMENT; RACE DIFFERENCE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ADULT; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; HYPERTENSION, MALIGNANT; LONGITUDINAL STUDIES; MALE; NETHERLANDS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84864371299     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-71     Document Type: Article

References (23)

1. Some different types of essential hypertension: their course and prognosis. Keith NM, Wagener HP, Barker NW, Am J Med Sci 1939 196 332 343
2. Complications and survival of 315 patients with malignant-phase hypertension. Lip GY, Beevers M, Beevers DG, J Hypertens 1995 13 915 924 10.1097/00004872-199508000-00013 8557970
3. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA, J Hypertens 2006 24 2299 2304 10.1097/01.hjh.0000249710.21146.38 17053554
4. Vascular lesions of malignant essential hypertension. Sanerkin NG, J Pathol 1971 103 177 184 10.1002/path.1711030306 5567174
5. Improving survival of malignant hypertension patients over 40years. Lane DA, Lip GY, Beevers DG, Am J Hypertens 2009 22 1199 1204 10.1038/ajh.2009.153 19696746
6. Microangiopathic hemolysis and renal failure in malignant hypertension. van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA, Hypertension 2005 45 246 251 10.1161/01.HYP.0000151620.17905.ee 15596574
7. The clinical presentation of malignant hypertension in Nigerians. Kadiri S, Olutade BO, J Hum Hypertens 1991 5 339 343 1956031
8. Dutch Renal Registry (RENINE) 2010 https://www.renine.nl/page?id= home&lang=en
9. US Renal Data System 2010 Annual Data Report. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, et al. Am J Kidney Dis 2011 57 A8 1-A8 526
10. The 2008 ERA-EDTA Registry Annual Report-a precis. Stel VS, van de Luijtgaarden MW, Wanner C, Jager KJ, NDT Plus 2011 4 1 13 10.1093/ndtplus/sfq191 21245934
11. Recovery of renal function in patients with accelerated malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril. Mourad G, Mimran A, Mion CM, Nephron 1985 41 166 169 10.1159/000183574 3900778
12. Recovery in malignant hypertension presenting as acute renal failure. Isles CG, McLay A, Jones JM, Q J Med 1984 53 439 452 6515000
13. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 461 470 10075613
14. Long-term prognosis in malignant or accelerated hypertension. Guerin C, Gonthier R, Berthoux FC, Nephrol Dial Transplant 1988 3 33 37 3132637
15. Long-term renal survival in malignant hypertension. Gonzalez R, Morales E, Segura J, Ruilope LM, Praga M, Nephrol Dial Transplant 2010 25 3266 3272 10.1093/ndt/gfq143 20299339
16. Blood pressure and end-stage renal disease in men. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J, N Engl J Med 1996 334 13 18 10.1056/NEJM199601043340103 7494564
17. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129mmHg. JAMA 1967 202 1028 1034 4862069
18. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114mmHg. JAMA 1970 213 1143 1152 4914579
19. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. Shea S, Misra D, Ehrlich MH, Field L, Francis CK, N Engl J Med 1992 327 776 781 10.1056/NEJM199209103271107 1501654
20. Persistent macrovascular and microvascular dysfunction in patients with malignant hypertension. Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GY, Hypertension 2011 57 490 496 10.1161/HYPERTENSIONAHA.110.166314 21263115
21. Renal function during long-term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension. Mitchell HC, Graham RM, Pettinger WA, Ann Intern Med 1980 93 676 681 7212474
22. Long-term survival after recovery from malignant nephrosclerosis. Nicholson GD, Am J Hypertens 1988 1 73 75 3370137
23. Reversible renal failure in malignant hypertension. Cordingley FT, Jones NF, Wing AJ, Hilton PJ, Clin Nephrol 1980 14 98 103 7408261